A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Children and Adolescents Age 5-17 With Autism Spectrum Disorder (ASD) - Trial 2020-003173-22
Access comprehensive clinical trial information for 2020-003173-22 through Pure Global AI's free database. This phase not specified trial is sponsored by F. Hoffmann-La Roche Ltd and is currently status unknown. The study focuses on Autism Spectrum Disorder.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2020-003173-22
Trial Details
EU Clinical Trials Register • 2020-003173-22
A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Children and Adolescents Age 5-17 With Autism Spectrum Disorder (ASD)
Study Focus
Sponsor & Location
F. Hoffmann-La Roche Ltd
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
1. Change From Baseline in Vineland-II Adaptive Behavior Scale Two Domain Composite (2DC) Score at Week 24
ICD-10 Classifications
Childhood autism
Atypical autism
Asperger syndrome
Neurotic disorder, unspecified
Mental and behavioural disorders
Data Source
EU Clinical Trials Register
2020-003173-22
Non-Device Trial